Pancreatic cancer targeted drugs

Erlotinib is a drug targeting epidermal growth factor receptor (EGFR). It blocks proliferation and survival signals of tumor cells by inhibiting EGFR activity. Erlotinib combined with chemotherapy can improve the efficacy of pancreatic cancer treatment to some extent. However, its effects are often limited and may cause side effects such as rash and diarrhea. In addition to erlotinib, there are other pancreatic cancer-targeting drugs currently under study and development. These drugs target different targets in an attempt to target tumor cells more precisely while reducing damage to normal tissues. For example, targeted drugs targeting certain gene mutations may show better efficacy in pancreatic cancer patients with the corresponding mutations. However, most of these drugs are still in clinical trials and more studies are needed to verify their effectiveness and safety. The selection of targeted drugs requires a combination of factors, including tumor characteristics, gene mutations, and physical conditions of patients. Accurate detection and analysis are essential to identify the right targeted drugs. In addition, the efficacy and side effects of drugs need to be closely monitored during treatment to adjust the treatment regimen in time. Pancreatic cancer-targeted drugs provide a new approach and hope for the treatment of pancreatic cancer, but their efficacy still needs to be further improved, and they need to be individually selected and applied according to the specific conditions of patients.